Unlearn

AI digital twins for clinical trials

Unlearn uses data, AI and digital twins to make clinical studies faster and more statistically robust, partnering with biopharmaceutical companies to redesign how trials are planned, run and analysed. Digital twins let a trial extract more statistical power from fewer participants, which shortens timelines without weakening conclusions — the trade-off that usually blocks acceleration in drug development. The company positions itself on scientific credibility rather than disruption alone, replacing uncertainty with AI-powered precision and committing to build that future rigorously alongside its clinical development partners.